FDA Rejects MDMA for Mental Health Treatment After Identifying Flawed Study Data
CCHR welcomes the FDA’s decision to disapprove the hallucinogenic drug, MDMA (Ecstasy) saying if approved, it would have fueled a planned $12 billion industry to…
CCHR welcomes the FDA’s decision to disapprove the hallucinogenic drug, MDMA (Ecstasy) saying if approved, it would have fueled a planned $12 billion industry to…
CCHR applauds the panel’s decision amid concerns over biased clinical trials and risks such as heart attacks, strokes, psychosis, and sexual abuse of patients during…
Mental health watchdog says adding psychedelics as approved mental health treatment will fuel more acts of drug-induced violence in the community. By Jan EastgatePresident, CCHR…
MDMA and psilocybin psychiatric research is a bad “trip” for mental health in Australia, U.S. and globally. By CCHR International The Mental Health Industry Watchdog…
By Kelly Patricia O’Meara May 28, 2015 Despite its well documented harmful and even life-threatening effects, a California psychiatrist and his partner, a therapist, have received…